Extended Data Fig. 1: High levels of CLCF1 in KRAS mutant lung adenocarcinoma (LUAD) are associated with decreased patient survival.
(a) CLCF1 expression is plotted as log2 transcripts per million (TPM) on the y-axis. Each cohort and group are plotted on the x-axis as LUAD (normal; tumor) and lung squamous cell carcinoma (LUSC) (normal; tumor), respectively. Each violin plot is overlaid with a boxplot depicting the maxima, upper quartile, median, lower quartile, and minima for each group. The sample sizes are shown below each plot as n = 59, 515, 511, and 501, respectively. P values were calculated with two-tailed unpaired Student’s t-test and corrected for multiple comparisons with Bonferroni adjustment. (b-e) Kaplan–Meier survival curves for LUAD samples. Samples sizes are listed on each plot. Hazard ratio and its respective P values were calculated with a multivariate Cox hazard regression correcting for age of diagnosis, gender, and cancer stage. Blue solid line represents the normal group (gene expression < 75th percentile) and red solid line represents the high group (gene expression > 75th percentile). (b) CLCF1 expression from samples with KRAS mutation. (c) CLCF1 expression from samples with no KRAS mutations. (d) CNTFR expression from samples with KRAS mutation. (e) CNTFR expression from samples with no KRAS mutations. (f) IL6ST (gp130) expression from samples with KRAS mutation. (g) IL6ST (gp130) expression from samples with no KRAS mutations. (h) LIFR expression from samples with KRAS mutation. (i) LIFR expression from samples with no KRAS mutations. HR = adjusted hazard ratio; CI = confidence interval for the adjusted hazard ratio.
